Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1981 2
1987 1
1988 2
1990 1
1992 1
1993 1
1994 5
1995 2
1996 2
1997 2
1998 5
1999 3
2000 4
2001 5
2003 1
2004 4
2009 2
2013 1
2014 1
2015 1
2018 6
2019 6
2020 5
2021 7
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.
Taavitsainen S, Engedal N, Cao S, Handle F, Erickson A, Prekovic S, Wetterskog D, Tolonen T, Vuorinen EM, Kiviaho A, Nätkin R, Häkkinen T, Devlies W, Henttinen S, Kaarijärvi R, Lahnalampi M, Kaljunen H, Nowakowska K, Syvälä H, Bläuer M, Cremaschi P, Claessens F, Visakorpi T, Tammela TLJ, Murtola T, Granberg KJ, Lamb AD, Ketola K, Mills IG, Attard G, Wang W, Nykter M, Urbanucci A. Taavitsainen S, et al. Nat Commun. 2021 Sep 6;12(1):5307. doi: 10.1038/s41467-021-25624-1. Nat Commun. 2021. PMID: 34489465 Free PMC article.
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G, Hakulinen P, Vuorela A, Joensuu H, Utriainen T, Fizazi K, Oksala R. Karimaa M, et al. Among authors: taavitsainen p. Mol Cancer Ther. 2022 Dec 2;21(12):1765-1776. doi: 10.1158/1535-7163.MCT-22-0115. Mol Cancer Ther. 2022. PMID: 36129801
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: taavitsainen s. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.
Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.
Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Cao S, et al. Among authors: taavitsainen s. Nat Biotechnol. 2022 Nov;40(11):1624-1633. doi: 10.1038/s41587-022-01342-x. Epub 2022 Jun 13. Nat Biotechnol. 2022. PMID: 35697807 Free PMC article.
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schönlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Grönberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW. Fonseca NM, et al. Among authors: taavitsainen s. Nat Commun. 2024 Feb 28;15(1):1828. doi: 10.1038/s41467-024-45475-w. Nat Commun. 2024. PMID: 38418825 Free PMC article.
Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine.
Nurminen A, Jaatinen S, Taavitsainen S, Högnäs G, Lesluyes T, Ansari-Pour N, Tolonen T, Haase K, Koskenalho A, Kankainen M, Jasu J, Rauhala H, Kesäniemi J, Nikupaavola T, Kujala P, Rinta-Kiikka I, Riikonen J, Kaipia A, Murtola T, Tammela TL, Visakorpi T, Nykter M, Wedge DC, Van Loo P, Bova GS. Nurminen A, et al. Among authors: taavitsainen s. Genome Med. 2023 Oct 12;15(1):82. doi: 10.1186/s13073-023-01242-y. Genome Med. 2023. PMID: 37828555 Free PMC article.
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Pelkonen O, et al. Among authors: taavitsainen p. Xenobiotica. 1998 Dec;28(12):1203-53. doi: 10.1080/004982598238886. Xenobiotica. 1998. PMID: 9890159 Review. No abstract available.
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen P, Prien O, Kähkönen M, Niehues M, Korjamo T, Denner K, Nykänen P, Vuorela A, Jungmann NA, von Bühler CJ, Koskinen M, Zurth C, Gieschen H. Taavitsainen P, et al. Drug Metab Dispos. 2021 Jun;49(6):420-433. doi: 10.1124/dmd.120.000309. Epub 2021 Mar 30. Drug Metab Dispos. 2021. PMID: 33785516 Clinical Trial.
Complete mass balance was achieved, with mean radioactivity recovery of 95.9% within 168 hours (63.4% in urine, 32.4% in feces). The administered 1:1 ratio of (S,R)- and (S,S)-darolutamide changed to approximately 1:5, respectively, in plasma. ...The two phar …
Complete mass balance was achieved, with mean radioactivity recovery of 95.9% within 168 hours (63.4% in urine, 32.4% in feces). The adminis …
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M, Chi KN, Wyatt AW. Herberts C, et al. Among authors: taavitsainen s. Eur Urol. 2020 Dec;78(6):834-844. doi: 10.1016/j.eururo.2020.04.058. Epub 2020 May 22. Eur Urol. 2020. PMID: 32451180
RESULTS AND LIMITATIONS: Of the patients, 6.0% (36/599) harboured somatic clonal activating mutation(s) in AKT1 or PIK3CA. Mutant allele-specific imbalance was common. ...
RESULTS AND LIMITATIONS: Of the patients, 6.0% (36/599) harboured somatic clonal activating mutation(s) in AKT1 or PIK3CA. Mutant all …
73 results